Bioneurals, Ltd. is a clinical research company that is committed to the development of drugs and medical products for the treatment of neurological diseases and metabolic disorders.
With a network of research laboratories and clinics across the Pacific Rim countries including Australia, New Zealand and Singapore. We are capable of designing and conducting animal studies, phase 1 to phase 3 clinical trials of therapeutic drugs for the treatment of Alzheimer's Disease, major depressive disorder, and obesity.
Bioneural, Limited has formed a strategic alliance with Biomed Industries, Inc., of San Jose, California, USA, in which Bioneurals serves as an exclusive research and clinical representative of Biomed in Australia and New Zealand for Biomed’s products.
Bioneurals, Limited is conducting animal studies in a network of research laboratories in this region.
In addition, Bioneurals is conducting clinical trials of Biomed’s drugs, such as NA-831 for the treatment of Alzheimer’s Disease, NA-901 for the treatment of Major Depressive Disorder, and NA-931 for the treatment of obesity in Australia and New Zealand.
Learn more
Sponsors in Europe and North America are facing increased challenges in participant recruitment and retention, lengthy timeframes and relatively high costs.
With a network of testing sites in Asia-Pacific region, Bioneurals offers large patient population, accessibility to key opinion leaders (KOLs) and medical facilities, government support for clinical trials, at cost-effective manner with high-quality standards and expedited regulatory environment.
Learn more
The regulatory environment in Australia and New Zealand offers a significant strategic opportunity for international biopharmaceutical companies who can take advantage of a uniquely fast and pragmatic regulatory pathway for early phase clinical trials.
Bioneurals is able to provide gap analysis and critical assessment of client’s clinical data to ensure our client’s package is ready and suitable for submission
The simplicity and efficiency of the Australian and New Zealand Regulatory and Ethics (IRB) processes often means our clients can defer regulatory submissions in other regions by initiating their clinical programs in Australia and/or New Zealand and commencing subject treatment within a single review cycle of 6-8 weeks from submission.